Research any topic before you write.

Find related topics.Discover entities.See connections.Build a topical map.

Rofecoxib

Rofecoxib is a COX-2-selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea. Rofecoxib was approved in the United States by the Food and Drug Administration (FDA) in May 1999, and was marketed…

Art & Measurement

Interactive map loads when it comes into view.
Use the mouse wheel or two fingers (on touchscreens) to zoom in and out of the map.

Topic orientation

Rofecoxib at a glance

The strongest research directions include Litigation. Use the connected concepts below as starting points, not as a keyword checklist.

Class actionsWrongful deathAlabamaTexasCardiac arrhythmiaCOX-2-selectiveNonsteroidal anti-inflammatory drugMerck & Co.

Research this topic

Explore the main themes, entities and connections around Rofecoxib. Start with the topic map, then use the sections below for research and deeper semantic analysis.

Explore this topic

Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.

Key facts & relationships

High-confidence facts extracted from structured source data. Use them as anchors for further research.

3D model (JSmol)
Interactive image
ATC code
M01AH02 (WHO)
Bioavailability
93%
CAS Number
162011-90-7 Y
ChEBI
CHEBI:8887 Y
ChEMBL
ChEMBL122 Y

Topics to explore

A structured outline of related entities, concepts and subtopics. Open any item to build a new map centered on it.

Browse the full topic structure. Each item opens a new analysis centered on that subject.

Overview

Mode of action

Efficacy

Withdrawal

Litigation

Possible return to market

Advanced semantic analysis

Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.

How this topic connects Entity context

Quick relationship hints grouped by predicate. Useful for spotting recurring semantic connections around the current entity.

See the strongest relationship patterns around the current topic before diving into the raw triples.

Rofecoxib

Top relations

related to Litigation · 17
Rofecoxib → Alabama, Atlantic City, By March, Carol Ernst, Humeston, Humeston's, Merck, Merck's, New Jersey, On August, On November, Robert Ernst, Rogers, Texas, The, This, US
related to FDA position · 13
Rofecoxib → American, Canada, Canadian, COX-2, Despite, FDA, FDA Advisory Committee, Following, In, Merck, NSAIDs, The, The FDA
related to Possible return to market · 13
Rofecoxib → COX-2, FDA, HA, In March, In November, It, Massachusetts-based Tremeau Pharmaceuticals, Merck, Traditional NSAIDs, Tremeau, TRM-201, United States, VIOXX
related to Mode of action · 11
Rofecoxib → Arcoxia, Bextra, By, Celebrex, COX, COX-1, COX-2, Cyclooxygenase, NSAIDs, Though, Vioxx
related to Withdrawal · 11
Rofecoxib → Americans, APPROVe, As, FDA, Furthermore, In, Merck, One FDA, Senior FDA, September, Vioxx
has effect · 3
Rofecoxib → Aside, In, NSAIDs
is a · 2
Rofecoxib → COX-2-selective nonsteroidal anti-inflammatory drug, selective COX-2 inhibitor
related to Efficacy · 2
Rofecoxib → FDA, When
3D model (JSmol) · 1
Rofecoxib → Interactive image
ATC code · 1
Rofecoxib → M01AH02 (WHO)

Important terminology Word statistics

Frequent words and multi-word phrases across the lead, headings, infobox and body. Useful for terminology coverage.

Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.

Important terminology

merck risk vioxx cardiovascular heart fda study nsaids cox-2 events data drug patients trial 2005 increased selective states studies market

Entity relationships Subject–Predicate–Object triples

Extracted RDF-like relationships with confidence and source. The table includes structured facts and lower-confidence contextual relations.
SubjectPredicateObjectConfidenceSrc
Rofecoxib3D model (JSmol)Interactive image1.00infobox
RofecoxibATC codeM01AH02 (WHO)1.00infobox
RofecoxibBioavailability93%1.00infobox
RofecoxibCAS Number162011-90-7 Y1.00infobox
RofecoxibChEBICHEBI:8887 Y1.00infobox
RofecoxibChEMBLChEMBL122 Y1.00infobox
RofecoxibChemSpider4911 Y1.00infobox
RofecoxibCompTox Dashboard (EPA)DTXSID20235671.00infobox
RofecoxibDrugBankDB00533 Y1.00infobox
RofecoxibECHA InfoCard100.230.0771.00infobox
RofecoxibElimination half-life17 hours1.00infobox
RofecoxibExcretionbile duct/kidney1.00infobox
RofecoxibFormulaC17H14O4S1.00infobox
RofecoxibIUPHAR/BPS28931.00infobox
RofecoxibKEGGD00568 Y1.00infobox
RofecoxibLegal statuswithdrawn worldwide1.00infobox
RofecoxibMetabolismliver1.00infobox
RofecoxibMolar mass314.36 g·mol−11.00infobox
RofecoxibPregnancy categoryAU: C1.00infobox
RofecoxibPronunciation/ˌrɒfɪˈkɒksɪb/1.00infobox
RofecoxibProtein binding87%1.00infobox
RofecoxibPubChem CID50901.00infobox
RofecoxibRoutes of administrationBy mouth & i.m1.00infobox
RofecoxibTrade namesVioxx, Ceoxx, Ceeoxx, others1.00infobox
RofecoxibUNII0QTW8Z7MCR1.00infobox
Rofecoxibis aCOX-2-selective nonsteroidal anti-inflammatory drug0.90text
Rofecoxibis aselective COX-2 inhibitor0.90text

Related concept clusters Concept neighborhoods

Clusters of nearby vocabulary surrounding the topic. Scan them for adjacent concepts and language you may have missed.

These clusters group vocabulary that occurs around closely connected concepts in the source material.

    Connections between topic areas Semantic bridges

    Bridge nodes connect otherwise separate parts of the map. Expand a row to inspect the topic groups on each side.

    Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.

    Map overview Semantic statistics

    Number of nodes, edges, triples, density and central hubs. Use it to gauge the size and connectivity of the map.

    Rofecoxib

    Nodes64
    Edges63
    Triples106
    Avg. degree1.97
    Density0.03125
    Components1
    For writers, content strategists, SEOs, marketers and creators — from quick topic research to advanced semantic analysis.